Service de Neurologie, CHRU Montpellier, Hopital Gui de Chauliac, Montpellier Cedex 5, France.
J Nutr Health Aging. 2010 Jan;14(1):37-44. doi: 10.1007/s12603-010-0007-z.
Dementia and Parkinsonism are two major neurodegenerative disorders. Accurate diagnosis can be difficult when patients have both syndromes because of a wide range of etiologies.
To improve clinical diagnosis, we propose a disease classification based on the pathological proteins which are involved in the neuropathological disease process.
Four neuropathological classes are proposed based on four major proteins, tau, A beta, alpha -synuclein and TDP43 : 1/ Tauopathy and amyloidopathy with possible Parkinsonism, 2/ Tauopathy with predominant Parkinsonism, 3/ Synucleinopathies with cognitive impairment/dementia and 4/ The TAR DNA binding protein 43 (TDP-43). This classification raises certain questions in clinical practice due to intriguing overlaps between clinical presentations despite the same pathological protein being involved.
The development of molecular and pathological protein research in neurodegenerative disorders can help classify the clinical association of dementia and Parkinsonism and improve therapeutic strategies against proteins involved in the degenerative process.
痴呆症和帕金森病是两种主要的神经退行性疾病。由于病因广泛，当患者同时患有这两种综合征时，准确诊断可能很困难。
为了改善临床诊断，我们提出了一种基于参与神经病理疾病过程的病理蛋白的疾病分类。
基于四种主要蛋白（tau、Aβ、α-突触核蛋白和 TDP43）提出了四种神经病理分类：1/tau 病和淀粉样变伴可能的帕金森病，2/tau 病伴主要帕金森病，3/突触核蛋白病伴认知障碍/痴呆，4/TAR DNA 结合蛋白 43（TDP-43）。由于尽管涉及相同的病理蛋白，但临床表现存在有趣的重叠，因此这种分类在临床实践中引发了一些问题。
分子和病理蛋白研究在神经退行性疾病中的发展可以帮助分类痴呆症和帕金森病的临床关联，并改善针对退行性过程中涉及的蛋白的治疗策略。
